Fiduciary Trust Co Grows Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Fiduciary Trust Co lifted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.0% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 10,175 shares of the medical equipment provider’s stock after acquiring an additional 485 shares during the quarter. Fiduciary Trust Co’s holdings in Intuitive Surgical were worth $4,999,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of ISRG. Ridgewood Investments LLC purchased a new position in Intuitive Surgical in the 2nd quarter worth approximately $26,000. Godsey & Gibb Inc. grew its holdings in Intuitive Surgical by 140.0% during the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 35 shares in the last quarter. LRI Investments LLC purchased a new stake in Intuitive Surgical during the 1st quarter worth $30,000. LGT Financial Advisors LLC lifted its holdings in Intuitive Surgical by 415.4% in the 2nd quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 54 shares in the last quarter. Finally, MidAtlantic Capital Management Inc. acquired a new stake in shares of Intuitive Surgical during the third quarter valued at about $33,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Trading Down 0.7 %

Shares of NASDAQ ISRG opened at $538.55 on Friday. Intuitive Surgical, Inc. has a 12-month low of $304.50 and a 12-month high of $552.00. The company has a market cap of $191.82 billion, a PE ratio of 86.58, a P/E/G ratio of 5.30 and a beta of 1.39. The stock has a 50 day simple moving average of $508.91 and a 200-day simple moving average of $467.29.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.32. The company had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.01 billion. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. Sell-side analysts forecast that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Insider Activity at Intuitive Surgical

In other news, General Counsel Gary Loeb sold 300 shares of Intuitive Surgical stock in a transaction on Monday, September 9th. The stock was sold at an average price of $475.00, for a total transaction of $142,500.00. Following the transaction, the general counsel now directly owns 1,595 shares in the company, valued at approximately $757,625. This trade represents a 15.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Jamie Samath sold 108 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $542.06, for a total value of $58,542.48. Following the completion of the sale, the chief financial officer now owns 8,757 shares of the company’s stock, valued at approximately $4,746,819.42. This trade represents a 1.22 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,459 shares of company stock worth $26,080,251 in the last 90 days. Corporate insiders own 0.90% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. The Goldman Sachs Group set a $604.00 price objective on Intuitive Surgical in a research note on Friday, October 18th. Mizuho upped their price target on shares of Intuitive Surgical from $440.00 to $500.00 in a report on Thursday, October 17th. Piper Sandler reissued an “overweight” rating and set a $538.00 price objective (up from $495.00) on shares of Intuitive Surgical in a report on Friday, October 18th. Truist Financial increased their price target on shares of Intuitive Surgical from $520.00 to $570.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Finally, Citigroup boosted their price objective on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average price target of $526.06.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.